Sage Therapeutics (SAGE) to Release Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE) is set to announce its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of ($1.53) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.02). The firm had revenue of $8.65 million for the quarter, compared to analysts’ expectations of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. Sage Therapeutics’s revenue was up 249.8% compared to the same quarter last year. During the same period last year, the firm earned ($2.68) EPS. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE opened at $8.01 on Monday. The business’s 50 day simple moving average is $7.53 and its 200-day simple moving average is $10.10. The firm has a market capitalization of $482.06 million, a price-to-earnings ratio of -0.95 and a beta of 0.91. Sage Therapeutics has a 12 month low of $5.84 and a 12 month high of $28.26.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SAGE shares. JPMorgan Chase & Co. cut their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, August 6th. Scotiabank decreased their price target on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating on the stock in a research note on Thursday, July 25th. TD Cowen cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $16.00 to $10.00 in a research note on Tuesday, July 30th. Robert W. Baird cut their price target on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday, October 9th. Finally, HC Wainwright restated a “neutral” rating and set a $25.00 price objective on shares of Sage Therapeutics in a report on Wednesday, October 9th. Two equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $13.76.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.